Oragenics Announces new President, Chief Executive Officer and Member of the Board of Directors June 6, 2016
Oragenics, Inc. Announces Notification of Noncompliance with NYSE MKT Continued Listing Standards May 13, 2016
Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol May 2, 2016
Oragenics Shareholders Re-elect Existing Board of Directors; Approve and Ratify other Proposals July 17, 2015
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral Cavity June 10, 2015
